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sitivity analyses proved the robustness of the results. With a probability of exceed-
ing 90%, the triple combination is cost effective with an incremental cost
effectiveness ratio (ICER) threshold of less than 20,000 €/QALY.CONCLUSIONS:The
single pill triple combination therapy with AML/VAL/HCTZ is a highly cost-effec-
tive antihypertensive choice for the treatment of moderate to severe hypertension.
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OBJECTIVES: To undertake an economic evaluation of rivaroxaban relative to stan-
dard care with injectable heparins (enoxaparin) followed by dose adjusted vitamin-
K-antagonists for the treatment of deep vein thrombosis (DVT). METHODS: An
international Markov model designed to reflect the management and complica-
tions of DVT in the course of three month cycles, up to death, was locally adapted.
It comprises twelve health states and allows for the comparison of rivaroxaban
against standard treatment in the six-month acute treatment phase. Baseline
event rates and the relative treatment effect of rivaroxaban (HRs) were derived
from the whole study population of the EINSTEIN DVT trial. Utility values were
based on the published literature. Cost data reflect the year 2012 and were ex-
tracted from local sources. The incremental cost-effectiveness ratio (ICER) was
calculated with quality-adjusted-life-years (QALYs) gained as the outcome mea-
sure. One-way sensitivity analyses and probabilistic analysis was undertaken to
deal with uncertainty. The analysis was undertaken from a payer perspective and
all costs and outcomes were discounted at 3.5%. RESULTS: The analysis showed
that the average total cost of 6-month rivaroxaban-treated patients was €170
higher compared to patients treated with the standard care. Rivaroxaban was as-
sociated with additional drug costs (€457), however these were partially offset by
reduced monitoring costs (€257). Moreover, rivaroxaban was associated with a
small QALY increment (0.019) and the ICER was calculated at €8,795 per QALY
gained. Sensitivity analysis showed that the base case ICER was most sensitive to
HRs for recurrent venous thromboembolism and major bleeds. Excluding the cost
of rivaroxaban, the model was also relatively sensitive to mean cohort age. Proba-
bilistic analysis revealed that the likelihood of rivaroxaban being cost-effective at a
threshold of €30,000/QALY was 89% and at €40,000 was 93%. CONCLUSIONS: Rivar-
oxaban may represent a cost-effective new alternative for the management of DVT
in Greece.
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OBJECTIVES: Ivabradine is a new therapeutic option for symptomatic heart failure
(HF) patients with reduced ejection fraction in sinus rhythm. SHIFT was an inter-
national, phase III, multicenter, randomized trial comparing ivabradine added to
standard care (SC) with SC alone in heart failure patients. Cardiovascular death or
hospitalization due to worsening HF was observed significantly less with ivabra-
dine than with placebo (hazard ratio 0.82, 95%CI: 0.75-0.90, P0.0001). In this study
we used Turkish data to evaluate cost effectiveness of ivabradine added to SC vs SC
alone in HF patients in a Turkish setting from national health care provider
perspective. METHODS: We used a two-state Markov cohort model (alive vs dead)
with a one-month cycle. Ivabradine added to SC was compared with SC alone based
on raw data of SHIFT trial. Health benefit modeled was life-years gained. Time
horizon was “lifetime”. The model considers direct costs only. Health care re-
sources were hospitalization, medications, HF management (1USD 1.7681TL; Feb
2012) and costs associated are collected from Ministry of Health and National Social
Security Organization lists. GDP per capita is 10.444USD in Turkey (2011). One-way
and probabilistic sensitivity analyses were performed with changes in model pa-
rameters, ie baseline heart rate, NYHA class, hospitalization rate etc. RESULTS:
Total costs were 17.225USD for ivabradine added to SC and 13.754USD for SC alone.
Life-years gained with ivabradine added to SC were 0.384; incremental cost-effec-
tiveness ratio was calculated as 9.040USD/LY gained. ICER value was robust to most
model parameters, but was sensitive to baseline heart rate and hospitalization rate
ratio. CONCLUSIONS: Ivabradine added to SC was cost effective in HF patients in
sinus rhythm in a Turkish setting (lower than GDP per capita in Turkey and in line
with WHO recommendations). This finding is based on significant decrease in
mortality and hospitalizations and related costs provided with ivabradine.
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OBJECTIVES: To compare the cost effectiveness of adding ezetimibe on top of
atorvastatin therapy vs. doubling of atorvastatin dose for high risk patients who
failed to reach target LDL cholesterol (LDL-C) levels on their current atorvastatin
dose. METHODS: A previously developed Markov model was utilized to evaluate
cost and health outcomes converted into quality adjusted life-years (QALY). The
lipid-lowering effects of the addition of ezetimibe (10mg) on top of atorvastatin
(20mg) (EZA) vs. doubling of existing atorvastatin (10 or20mg to 20 or 40 mg) (2A)
doses were estimated from clinical trial data. High risk cohort was defined as those
with established coronary heart disease (CHD) and/or diabetes. Patient profile data
were generated based on the LTAP-2 study in Brazil. Costs of acute and long-term
care for CHD events and treatments were calculated in Brazilian Reals (R$).
RESULTS:Discounted costs and QALYs ranged from R$ 13,576 to R$ 57,273 and 5.99
to 15.59 respectively for 2A arm whereas ranges for discounted costs and QALYs
were R $15,673 to R$ 60,735 and 6.16 to 15.64 respectively for EZA among 54
patients with CHD and/or diabetes. Incremental cost-effectiveness ratios (ICERs)
comparing EZA vs. 2A were estimated to range between R$ 13,392 to R$ 75,883
(ICER exceeded R$ 60,000 only for 4 patient profiles). These results suggest that
EZA was cost-effective against 2A at a threshold of 3 times Brazilian per capita
GDP (R$ 60,000) for majority of the patients (50 out of 54 patient profiles). In
addition, for patients with CHD and diabetes, EZA was highly cost-effective (ICER
less than Brazilian GDP per capita R$ 20,000) against 2A. CONCLUSIONS: Results
suggested that adding ezetimibe to atorvastatin among high risk patients who
were not at LDL-C goal could be a cost-effective treatment strategy when compared
to doubling of atorvastatin dose.
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Heart failure (HF) represents a significant economic burden worldwide with hospi-
talizations as main cost driver. Ivabradine, has been granted in the treatment of
symptomatic heart failure patients, based on SHIFT trial. OBJECTIVES: To evaluate
the cost-effectiveness of Ivabradine on top of standard care of heart failure versus
standard care alone in Thai patients from the national health care perspective.
METHODS: An economic evaluation based on clinical benefits observed and re-
sources consumed during the SHIFT, a randomized placebo-controlled trial, with
ivabradine on top of standard care compared to standard care alone with a mean
follow up of 22.9 months. The principal results were -18% and -26% relative risk
reduction from cardiovascular death or hospitalization for heart failure and hos-
pitalization for worsening heart failure. Risk equations were built based on SHIFT
data, adjusting clinical benefits to Thai patient profile obtained from literature
review. Drug local costs were the lowest median prices from ministry of public
health database. Hospital costs were extracted from a public hospital database on
HF admission during January-December 2011 representing 1,276 patient-treatment
days, with mean hospital charges combined in Thai baht(THB). The incremental
cost-effectiveness ratios (ICER) were calculated and expressed in cost/life years
gained (LYG) and cost/Quality-Adjusted Life Years gained (QALYg). Probabilistic
sensitivity analysis was performed. RESULTS: Mean total cost [95% CI], LY and
QALY gained were 224,880 [220,470 - 228,978] THB, 2.12 LY and 1.52 QALY respec-
tively, for Thai heart failure patients treated by ivabradine on top of standard care,
while 227,884 [222,736-232,667] THB, 2.09 LY and 1.49 QALY respectively for pa-
tients treated by standard care alone. As results, ivabradine on top of standard care
provided an ICER of 134,281THB/LYG and 109,415THB/QALYg compared with stan-
dard care alone. CONCLUSIONS: Ivabradine on top of standard care treatment for
Thai heart failure patient is dominant as compared with standard care alone re-
sulting in LYG, QALY gains of 134,281THB and 109,415 THB.
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OBJECTIVES: To evaluate cost effectiveness of amlodipine (aml) / valsartan (val) /
hydrochlorothiazide (hctz) single pill combination(SPC) versus aml/val or val/hctz
SPCs. METHODS: The efficacy results of the SPCs evaluated will be obtained from a
randomized controlled study conducted by Calhoun DA et.al. Price of the SPCs
evaluated will be obtained from price list of the Ministry of Health of Turkey.
Aml/Val 10/320 mg is not available in Turkish market, therefore its price will be
estimated by using regression model based on the prices of the other available
antihypertensives in the Turkey. Cost-effectiveness (CE) ratio for each SPC was
calculated and SPCs will be compared in terms of incremental cost-effectiveness
ratio (ICER). RESULTS: The ratio of patients achieving blood pressure (BP) rates
were 70.8%, 54.1% and 48.3% with aml/val/hctz 10/320/25 mg, aml/val 10/320 mg
and val/hctz 320/25 mg, respectively (1). The drug costs of the aml/val/hctz 10/
320/25 mg, aml/val 10/320 mg and val/hctz 320/25 mg 9-weeks treatments for 100
patients are 14,161 TL, 11,692 TL and 5,962 TL, respectively. The CE ratios of aml/
val/hctz 10/320/25 mg, aml/val 10/320 mg and val/hctz 320/25 mg are calculated as
2.0, 2.16 and 1.23 respectively. Thirty-day adjusted ICERs of aml/val/hctz 10/320/25
mg are 70.40 TL and 173.52 per percentage of patients achieving BP targets versus
aml/val 10/320 mg and val/hctz 320/25 mg, respectively, whereas it is 470.44 TL with
aml/val 10/320 mg versus val/hctz 320/25 mg. CONCLUSIONS: Although there is no
formal threshold for ICER per percentage of patients achieving BP targets in Turkey,
reimbursement of aml/val/hctz 10/320/25 mg seems to be affordable.
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